The uncertain path to authorisation in the US for Novavax despite passing the efficacy test with an impressive score of 90.4% might see India emerge as a major destination for the shots with the Serum Institute of India as manufacturing partner.from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3gvSYAh
0 Comments:
Post a Comment